Actavis Plc’s purchase of Forest Laboratories Inc. (FRX) accelerates a pharmaceutical merger wave that stands to engulf even more drugmakers. The $21 billion transaction, which includes Forest’s net cash, is fueling the busiest 12-month period for acquisitions in the industry since 2009, according to data compiled by Bloomberg. Generic-drug companies such as Actavis and Valeant Pharmaceuticals International Inc. (VRX) are boosting growth by crossing over into specialty medicines including skin-care treatments, birth control and remedies for digestive diseases.
Help employers find you! Check out all the jobs and post your resume.
